Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as
obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with …

Second-generation antipsychotics (SGA) are being used more often than ever before in
children and adolescents with psychotic and a wide range of non-psychotic disorders …

Antipsychotics are effective in preventing relapses of schizophrenia, but it is generally
believed that their long‐term use is harmful for patients' physical well‐being. However, there …

Importance Although adults with schizophrenia have a significantly increased risk of
premature mortality, sample size limitations of previous research have hindered the …

The lifespan of people with severe mental illness (SMI) is shorter compared to the general
population. This excess mortality is mainly due to physical illness. We report prevalence …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

BackgroundDespite increased cardiometabolic risk in individuals with mental illness taking
antipsychotic medication, metabolic screening practices are often incomplete or …

Background: Antipsychotic-related weight gain and metabolic adverse effects have become
a major focus, especially in youth. Methods: Review of randomized, cohort, and …

Despite treatment advances over the past decades, schizophrenia remains one of the most
severe psychiatric disorders that is associated with a chronic relapsing course and marked …

Determinants of antipsychotic selection and response include parameters of the primary
disorder, psychiatric and physical comorbidities, past treatment effects, patient preferences …